Stefano Francesco Crinò1, Mirko D'Onofrio2, Laura Bernardoni3, Luca Frulloni3, Michele Iannelli2, Giuseppe Malleo4, Salvatore Paiella4, Alberto Larghi5, Armando Gabbrielli3. 1. Gastroenterology and Digestive Endoscopy Unit, The Pancreas Institute, G.B. Rossi University Hospital, Verona, Italy. stefanocrino@hotmail.com or stefanofrancesco.crino@aovr.veneto.it. 2. Department of Radiology, G.B. Rossi University Hospital, Verona, Italy. 3. Gastroenterology and Digestive Endoscopy Unit, The Pancreas Institute, G.B. Rossi University Hospital, Verona, Italy. 4. Department of Pancreatic Surgery, The Pancreas Institute, G.B. Rossi University Hospital, Verona,Italy. 5. Digestive Endoscopy Unit, Catholic University, Rome, Italy.
Abstract
BACKGROUND AND AIMS: Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) is a promising technique for the treatment of pancreatic neoplasm. We evaluated the feasibility, safety, and technical success of pancreatic EUS-RFA performed in a single center. METHODS: 9 consecutive patients (8 with pancreatic adenocarcinoma and 1 with renal cancer metastasis) were referred for EUS-RFA between November 2016 and July 2017. EUS-RFA was performed using 18-gauge internally cooled electrode with a 5 or 10 mm exposed tip. Feasibility, technical success or early and late adverse events were assessed. RESULTS: One patient was excluded because of a large necrotic portion. EUS-RFA was feasible in all the other 8 (100%) cases. An ablated area inside the tumor was achieved in all treated patients. No early or late major adverse event was observed after a mean follow-up of 6 months. Three patients experienced mild post-procedural abdominal pain. CONCLUSIONS: EUS-RFA seems a feasible, safe, and effective procedure for pancreatic neoplasms. Its role in the treatment and management of pancreatic masses must be further investigated.
BACKGROUND AND AIMS: Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) is a promising technique for the treatment of pancreatic neoplasm. We evaluated the feasibility, safety, and technical success of pancreatic EUS-RFA performed in a single center. METHODS: 9 consecutive patients (8 with pancreatic adenocarcinoma and 1 with renal cancer metastasis) were referred for EUS-RFA between November 2016 and July 2017. EUS-RFA was performed using 18-gauge internally cooled electrode with a 5 or 10 mm exposed tip. Feasibility, technical success or early and late adverse events were assessed. RESULTS: One patient was excluded because of a large necrotic portion. EUS-RFA was feasible in all the other 8 (100%) cases. An ablated area inside the tumor was achieved in all treated patients. No early or late major adverse event was observed after a mean follow-up of 6 months. Three patients experienced mild post-procedural abdominal pain. CONCLUSIONS: EUS-RFA seems a feasible, safe, and effective procedure for pancreatic neoplasms. Its role in the treatment and management of pancreatic masses must be further investigated.
Authors: Mariana Figueiredo Ferreira; Rodrigo Garces-Duran; Pierre Eisendrath; Jacques Devière; Pierre Deprez; Laurent Monino; Jean-Luc Van Laethem; Ivan Borbath Journal: Endosc Int Open Date: 2022-10-17
Authors: Muhammad Nadeem Yousaf; Hamid Ehsan; Ahmad Muneeb; Ahsan Wahab; Muhammad K Sana; Karun Neupane; Fizah S Chaudhary Journal: Front Med (Lausanne) Date: 2021-02-11